An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

Published:2022-08-04 Issue:1 Volume:14 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Cowles Sarah C.¹²,Sheen Allison¹³,Santollani Luciano¹²,Lutz Emi A.¹³,Lax Brianna M.¹²,Palmeri Joseph R.¹²,Freeman Gordon J.⁴,Wittrup K. Dane¹²³

Affiliation:

1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

2. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

3. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

4. Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

Funder

NIH

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2022.2088454

Reference63 articles.

1. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

2. PD-1 and Its Ligands in Tolerance and Immunity

3. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

4. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

5. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction;mAbs;2024-06-07

2. Preclinical development of novel PD-L1 tracers and first-in-human study of [⁶⁸Ga]Ga-NOTA-RW102 in patients with lung cancers;Journal for ImmunoTherapy of Cancer;2024-04

3. Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies;Current Opinion in Biotechnology;2023-12

4. Advancing protein therapeutics through proximity-induced chemistry;Cell Chemical Biology;2023-10

5. Spatiotemporally programming cytokine immunotherapies through protein engineering;Immunological Reviews;2023-07-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3